Skip to content
Back to MNKD

Mannkind Corp

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
13
Purchases
0
Sales
13
Purchase value
$0.00
Sale value
$3.16M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Steven B. BinderDirector
4Rule 10b5-1 plan disclosed
Filed Sep 28, 2026Period of report Sep 25, 20260001193125-26-405736
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 25, 2026
Common Stock, $0.01 Par ValueF1F239,051$3.29$128.48K713,258Direct
Filing footnotes · 2
  1. F1Transaction occurred pursuant to Rule 10B5-1 Plan established December 2, 2025.
  2. F2The weighted average sales price of the reported transaction was $3.29 based on a range of prices between $3.20 and $3.36. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Open on SEC EDGAR
Steven B. BinderDirector
4Rule 10b5-1 plan disclosed
Filed Sep 14, 2026Period of report Sep 10, 20260001193125-26-391003
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 10, 2026
Common Stock, $0.01 Par ValueF1F233,558$3.81$127.86K752,309Direct
Filing footnotes · 2
  1. F1Transaction occurred pursuant to Rule 10B5-1 Plan established December 2, 2025.
  2. F2The weighted average sales price of the reported transaction was $3.81 based on a range of prices between $3.76 and $3.87. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Open on SEC EDGAR
Steven B. BinderDirector
4Rule 10b5-1 plan disclosed
Filed Aug 10, 2026Period of report Aug 7, 20260001193125-26-343016
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 7, 2026
Common Stock, $0.01 Par ValueF2F139,051$4.06$158.55K785,867Direct
Filing footnotes · 2
  1. F1Transaction occurred pursuant to Rule 10B5-1 Plan established December 2, 2025.
  2. F2The weighted average sales price of the reported transaction was $4.06 based on a range of prices between $3.86 and $4.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Open on SEC EDGAR
David ThomsonEVP Genl Counsel & Secretary
4Rule 10b5-1 plan disclosed
Filed Jul 17, 2026Period of report Jul 15, 20260001193125-26-308131
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 17, 2026
Common Stock, $0.01 Par ValueF4F324,109$4.05$97.64K797,554Direct
Filing footnotes · 5
  1. F1A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.
  2. F2Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.
  3. F3Transaction occurred pursuant to Rule 10B5-1 Plan established December 2, 2025.
  4. F4The weighted average sales price of the reported transaction was $4.05 based on a range of prices between $3.98 and $4.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  5. F5Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
Open on SEC EDGAR
Steven B. BinderDirector
4Rule 10b5-1 plan disclosed
Filed Jul 17, 2026Period of report Jul 15, 20260001193125-26-308129
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 17, 2026
Common Stock, $0.01 Par ValueF4F352,485$4.06$213.09K824,918Direct
Filing footnotes · 5
  1. F1A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.
  2. F2Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.
  3. F3Transaction occurred pursuant to Rule 10B5-1 Plan established December 2, 2025.
  4. F4The weighted average sales price of the reported transaction was $4.06 based on a range of prices between $3.98 and $4.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  5. F5Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
Open on SEC EDGAR
Steven B. BinderDirector
4Rule 10b5-1 plan disclosed
Filed May 13, 2026Period of report May 11, 20260001193125-26-222311
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 12, 2026
Common Stock, $0.01 Par ValueF2F316,940$3.29$55.73K808,008Direct
Filing footnotes · 3
  1. F1Represents shares withheld to pay tax withholding obligations due on the date of vesting of the Restricted Stock Units originally granted on May 10, 2022.
  2. F2Transaction occurred pursuant to Rule 10B5-1 Plan established December 2, 2025.
  3. F3The weighted average sales price of the reported transaction was $3.29 based on a range of prices between $3.25 and $3.34. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Open on SEC EDGAR
David ThomsonEVP Genl Counsel & Secretary
4Rule 10b5-1 plan disclosed
Filed May 13, 2026Period of report May 11, 20260001193125-26-222310
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 12, 2026
Common Stock, $0.01 Par ValueF2F33,033$3.29$9.98K826,299Direct
Filing footnotes · 3
  1. F1Represents shares withheld to pay tax withholding obligations due on the date of vesting of the Restricted Stock Units originally granted on May 10, 2022.
  2. F2Transaction occurred pursuant to Rule 10b5-1 Plan established August 27, 2025.
  3. F3The weighted average sales price of the reported transaction was $3.29 based on a range of prices between $3.25 and $3.34. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Open on SEC EDGAR
Stuart A TrossChief People & Workpl Officer
4Rule 10b5-1 plan disclosed
Filed Jan 9, 2026Period of report Jan 8, 20260001193125-26-009297
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 8, 2026
Common Stock, $0.01 Par ValueF147,006$6.33$297.55K985,007Direct
Filing footnotes · 1
  1. F1Transaction occured pursuant to Rule 10B5-1 Plan established June 17, 2025.
Open on SEC EDGAR
Michael CastagnaDirector · Chief Executive Officer
4Rule 10b5-1 plan disclosed
Filed Dec 19, 2025Period of report Dec 17, 20250001193125-25-327227
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 17, 2025
Common Stock, $0.01 Par ValueF1F265,804$6.01$395.48K2,504,792Direct
Filing footnotes · 2
  1. F1Transaction occurred pursuant to Rule 10b5-1 Plan established August 8, 2025.
  2. F2The weighted average sales price of the reported transaction was $6.01 based on a range of prices between $6.00 and $6.04. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Open on SEC EDGAR
Michael CastagnaDirector · Chief Executive Officer
4Rule 10b5-1 plan disclosed
Filed Dec 16, 2025Period of report Dec 12, 20250001193125-25-321366
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 16, 2025
Common Stock, $0.01 Par ValueF121,310$6.00$127.86K2,504,792Direct
SaleDec 12, 2025
Common Stock, $0.01 Par ValueF120,806$6.00$124.84K2,504,792Direct
Filing footnotes · 1
  1. F1Transaction occurred pursuant to Rule 10b5-1 Plan established August 8, 2025.
Open on SEC EDGAR
Michael CastagnaDirector · Chief Executive Officer
4Rule 10b5-1 plan disclosed
Filed Dec 4, 2025Period of report Dec 2, 20250001193125-25-308350
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 2, 2025
Common Stock, $0.01 Par ValueF1F2107,920$5.57$601.11K2,504,792Direct
Filing footnotes · 2
  1. F1Transaction occurred pursuant to Rule 10b5-1 Plan established August 8, 2025.
  2. F2The weighted average sales price of the reported transaction was $5.57 based on a range of prices between $5.50 and $5.63. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Open on SEC EDGAR
David ThomsonEVP Genl Counsel & Secretary
4Rule 10b5-1 plan disclosed
Filed Dec 4, 2025Period of report Dec 2, 20250001193125-25-308347
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 2, 2025
Common Stock, $0.01 Par ValueF1F2147,780$5.57$823.13K841,719Direct
Filing footnotes · 2
  1. F1Transaction occurred pursuant to Rule 10b5-1 Plan established August 27, 2025.
  2. F2The weighted average sales price of the reported transaction was $5.57 based on a range of prices between $5.50 and $5.63. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.